New Antifungal Drugs, New Approaches and Vaccines Antifungal name Choose antifungalAlbaconazoleAlpha-asaroneAmorolfineAR-12ASP2397 (VL-2397)ASP9726AuranofinAureobasidin ABHBMBiafungin (CD101)CD101Ceragenin CSA-131CorifunginE1210Encochleated AmB (MAT023)EV-086F901318 (olorofim)FG 3622FK506 (tacrolimus) and L-685,818FR290581General articlesGM 237354GriseofulvinHaemofunginIbomycinIbrexafungerp (SCY-078, MK-3118)Icofungipen (PLD-118)Ilicicolin HKOSN-2079 (polyketide)L365L743L884Macrocyclic amidinoureasManumycin AMAT2203MGCD290MycograbMyriocinNebulised AmpBNikkomycin ZNovamycin (NP339)Novexatin (NP213)P11-6PC945PolyoxinPradimicins (inc. BMS-181184)R-135853SampangineSM21SPK-843StatinsT-2307TacrolimusTavaborole (AN2690)TipifarnibTurbinmicinVaccinesVT-1129VT-1161VT-1598YO-001A Showing 9 posts of 219 posts found. Title Trail phase Date FDA Grants QIDP Designation to VT-1129 for Treatment of Cryptococcal Meningitis Phase 1 16 September 2015 Viamet begins phase IIb trial in RVVC Phase 2 16 February 2015 Viamet Pharmaceuticals; Viamet Announces Initiation of RENOVATE Phase 2b Study of Oral VT-1161 in Onychomycosis Phase 2 25 March 2015 Viamet to Provide Update on Novel Antifungal Programs at ECCMID 2015 Phase 2 24 April 2015 A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) Phase 2 8 October 2014 A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Onychomycosis of the Toenail Phase 2 8 October 2014 A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Moderate – Severe Interdigital Tinea Pedis Phase 2 1 December 2014 A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Acute Vaginal Candidiasis (Yeast Infection) Phase 2 1 March 2014 Viamet to Present at ICAAC/ICC 2015 10 September 2015 Previous1...13141516171819202122
